TOKYO, CAMBRIDGE (UK), August 10, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa,Ph.D., “Astellas”) and Quethera Limited (CEO: Peter Widdowson, Ph.D., “Quethera”) today announced that Astellas has acquired Quethera, a gene therapy company headquartered in the United Kingdom, that is focused on developing novel treatments for ocular disorders, such as glaucoma.
Investors 1
Mentions in press and media 2
| Date | Title | Description |
| 13.08.2018 | Term Sheet — Monday, August 13 | SOLVING THE TESLA PUZZLE
Good morning, Term Sheet readers.
Paid Content A.I. is the answer to protecting your enterprise in the cloud From ExtraHop
In a Q&A style blog post, Musk answers questions such as “Why did I make a public announ... |
| - | Parkwalk closes Quethera investment | We are pleased to announce that the University of Cambridge Enterprise Fund III has made an investment in Quethera, a gene therapy company spun-out of the University with a novel treatment for glaucoma. |
Reviews 0
